Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
6634.TWO
SELLREMOVESinew Pharma Inc. · Healthcare · Taiwan · $143M · Avg Vol: $576K/d
Sinew Pharma is a small Taiwanese healthcare company with low quality metrics (Q: 40). It lacks the scale and pricing power to navigate rising outsourced development and manufacturing costs, making it a poor fit.
COMPANY DESCRIPTION
Sinew Pharma Inc. is a clinical-stage biotechnology company dedicated to developing small-molecule therapeutics for metabolic and degenerative diseases, with a focus on NASH and sarcopenia. The company leverages its proprietary drug delivery and formulation platforms to repurpose and optimize existing compounds for new therapeutic indications. Sinew Pharma operates as a niche drug developer targeting high-value, unmet medical markets through global licensing strategies.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 10,364 | 0 | 0 | 1,485 | -47.7% |
| EPS | -0.05 | -0.06 | -0.08 | -0.07 | — | — |
| Shares | — | 69.8M | 71.2M | 71.3M | 71.3M | +2.2% |
| Debt | — | 0.2M | 0.3M | 89,102 | 0.5M | 26.3% |
| Equity | — | 46.1M | 41.8M | 37.8M | 34.5M | -9.2% |
| Op CF | — | -3.0M | -3.7M | -3.4M | -3.0M | — |
| Inv CF | — | -7.0M | 0.8M | -0.5M | 2.7M | — |
| Fin CF | — | 0.3M | 0.4M | -83,699 | -0.2M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 6634.TWO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 6634.TWO | Sinew Pharma Inc.(you) | $143M | 35 | SELL |
| 3176.TWO | Medigen Biotechnology Corp. | $146M | 28 | SELL |
| 4130.TWO | Genovate Biotechnology Co., Ltd. | $109M | 29 | SELL |
| 3205.TWO | Sagittarius Life Science Corp | $111M | 26 | SELL |
| 6794.TW | UnicoCell Biomed Co., Ltd. | $159M | 18 | STRONG SELL |
| 4142.TW | Adimmune Corporation | $229M | 25 | SELL |
| 6492.TWO | Senhwa Biosciences, Inc. | $121M | 17 | STRONG SELL |
| 6838.TW | Formosa Pharmaceuticals, Inc. | $116M | 15 | STRONG SELL |
| 4157.TWO | TaiGen Biopharmaceuticals Holdings Limited | $193M | 16 | STRONG SELL |
| 6547.TWO | Medigen Vaccine Biologics Corporation | $468M | 32 | SELL |
Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%